January 10th, 2011
Employee First Customer Wins
Author: Vikram Gulati, President & CEO, Intelligroup
I am very excited to share with you a significant shift in our go forward strategy. Going forward, we are adopting an “Employee First, Customer Wins (EFCW)” management philosophy. There are many reasons for doing this. One of the most important of them is to align our employees with our customers, the point of intersection where value is delivered. We want to empower our employees to realize their potential and deliver superior value to our customers, partners, and all stakeholders.
Continue reading Employee First Customer Wins (EFCW)
Tags:
Corporate Values, Customer Delight, HR initiatives
January 1st, 2011
Can Drug Development Lifecycle Time be reduced?
Author: Hitesh Verma, General Manager, Life Sciences Practice at Intelligroup
“Time to Market” is a key mantra for a product or a service to start contributing to business growth and results. While a typical product starts its commercial operation anywhere between 1 and 3 years since the inception of the idea, a new pharmaceutical drug takes typically between 8 and 10 years, after the patent has been filed, to be approved for commercial marketing. With about 15% of the new chemical entities discovered making it to the commercial market in the “Time to Market” of 8 – 10 years, pharmaceutical companies constantly ask the question – can the Drug Development Lifecycle be reduced?
Continue reading Can Drug Development Lifecycle Time be reduced?
Tags:
Life Sciences, Pharma, Pharmaceuticals
December 13th, 2010
Author: Murali Sundararajan, Associate Director, Global Life Sciences Practice, Intelligroup
The Pharmaceutical Industry Supply Chain is highly complex in nature because of the involvement of a huge number of stakeholders in the chain. Because of this complexity, the Pharmaceutical Supply Chain is the biggest challenge for the supply chain experts, as well as the pharmaceutical professionals.
Continue reading Supply Chain Visibility In Pharmaceutical Industry
Tags:
Life Sciences, Pharma, Pharmaceuticals, Supply Chain
December 13th, 2010
Author: Murali Sundararajan, Associate Director, Global Life Sciences Practice, Intelligroup
The Global Pharmaceutical market is poised to grow at the rate of 4-7% and expected to reach $ 975 bn by 2013 (Pharmtech) . This growth is on a Global scenario and has a stronger presence in US market. The therapeutic segments which fuel this huge Pharmaceutical growth are Cardiovascular and Anti diabetic drugs. Anti Hypertensive drug segment is another important area of Therapeutics which will be predominant in next few years. This is due to change in Lifestyle and demographic conditions across the Globe.
Continue reading Global Pharmaceutical IT Scenario and Landscape
Tags:
Life Sciences, Pharma, Pharmaceuticals
November 8th, 2010
Author: Sanjiv Shah, Head, Global Life Sciences Practice, Intelligroup
This past week a giant drug maker expanded the recall of their blockbuster cholesterol reduction medication bottles due to a musty odor in the bottles, bringing the total number of recalled bottles to more than 360,000. In the same week, another giant drug maker agreed to pay a $750 million fine for quality related violations at one of their plants that resulted in contaminated and mislabeled product entering the supply chain.
Continue reading What’s IT got to do with it? Rethinking the IT/QA Equation in Life Sciences
Tags:
Life Sciences
October 10th, 2010
Author: Sanjiv Shah, Head, Global Life Sciences Practice, Intelligroup
While counterfeit drugs have been around for decades, the internet’s growth and the popularity of Pfizer’s erectile dysfunction drug Viagra in the 1990s created the “perfect storm” to fuel this underground industry. Last year, nearly 1,700 incidents of counterfeit drugs were reported worldwide, triple the number in 2004, says the Pharmaceutical Security Institute (PSI), a group funded by drug makers. Estimates for the size of the counterfeit drug market range from $75 billion to $200 billion a year. Shockingly, 75% of fake drugs supplied globally have some origins in India, says Sanjiv Shah, head—global life sciences practice, Intelligroup, a leading provider of IT solutions to help drug companies counter the fake drug menace. In a recent interaction with BV Mahalakshmi, Shah lays emphasis on safety through traceability by means of epedigree, an electronic document being used by drug companies to protect consumers from fake medicines.Excerpts:
Continue reading INTERVIEW: SANJIV SHAH: ‘Fake drugs are a growing problem’
Tags:
Life Sciences
August 22nd, 2010
Author: Alok Pant, Senior Vice President, Global Marketing & Alliances
SMB customers have already adopted Tier 2 ERP packages as Software as A Service (SaaS) and are running their business critical processes. They are benefiting from lower costs, and flexibility to ramp up or down IT resources with the business.
Continue reading ERP as SaaS: Are Large Enterprises ready?
Tags:
cloud computing, ERP, SaaS
February 19th, 2010
Author: Vijay Reddy Gondesi, Practice Head, Global Business Intelligence
Due to the proliferation of data, there is a need for enterprises to gain insights to make better decisions. Companies are good in acquiring data over a period of years but poor in transforming that into meaningful information. BI (Business Intelligence) isn’t just reporting anymore.
Continue reading Enterprise Business Intelligence
Tags:
BI, Business Intelligence
December 9th, 2009
Author: Alok Pant, Senior Vice President, Global Marketing & Alliances
The cloud is on everyone’s mind today. At Intelligroup, we seek to decipher the hype from the reality, and bring clarity to the various avatars of the cloud–Software as A Service (SaaS), Platform As a Service (PaaS), Infrastructure As a Service (IaaS), or Business Process As a Service.
Continue reading Cloud Computing
Tags:
cloud computing
